# DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Mi

Source: https://onco.cc/trials/nct05770102/  
OnCo record `nct05770102` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of atezolizumab in colorectal cancer, run by Cancer Research UK, now recruiting.

## Summary

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition is a phase 2/3, interventional study registered as NCT05770102 by Cancer Research UK, with a registry enrolment figure of 30 participants, started 2023-10-25 and due to reach its primary completion in 2029-10. Interventions recorded: Atezolizumab. Conditions listed: Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Solid Tumours. Primary outcome: Objective Response (OR); Durable Clinical Benefit (DCB). Sites: United Kingdom. United Kingdom sites listed: 27. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: DETERMINE
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05770102
- Phase: 2/3
- Setting: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations.
- Sponsor: Cancer Research UK
- Enrolled: 30

## Notes

- UK sites (registry): Belfast City Hospital (Belfast); University Hospital Birmingham (Birmingham); Birmingham Children's Hospital (Birmingham); Bristol Royal Hospital for Children (Bristol); Bristol Haematology and Oncology Centre (Bristol); Addenbrooke's Hospital (Cambridge); Velindre Cancer Centre (Cardiff); Cardiff Children's Hospital (Cardiff); Western General Hospital (Edinburgh); The Beatson Hospital (Glasgow); Royal Hospital for Children Glasgow (Glasgow); Leicester Royal Infirmary (Leicester) and 15 more.

## Sources

- ClinicalTrials.gov NCT05770102: https://clinicaltrials.gov/study/NCT05770102

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05770102.json